Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 227

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 227
---
     |     |         7 |     |     |         7 |
| Rollover RSU awards outstanding                                                        |     |     |         3 |     |     |         3 |
| Stock options outstanding (minimum exercise price $571.20)                             |     |     |        64 |     |     |        64 |
| Shares reserved for issuance                                                           |     |     | 1,817,922 |     |     |     1,893 |
| Shares available for future stock grants under the 2021 Equity Incentive Plan          |     |     |    97,880 |     |     |     1,288 |
| Total common stock reserved for issuance                                               |     |     | 1,915,802 |     |     |     3,181 |

| (1) | 125,000 shares via the alternative cashless exercise and 62,500 shares via cash exercise |

F-36 8. Stock-Based Compensation 2021 Equity Incentive Plan In January 2022, the Board of Directors and the Company’s stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan is administered by the Board of Directors. Vesting periods and other restrictions for grants under the 2021 Plan are determined at the discretion of the Board of Directors. Grants to employees, officers, directors, advisors, and consultants of the Company typically vest immediately or within four years. In addition, the number of shares of stock available for issuance under the 2021 Plan will be automatically increased each January 1 by 10% of the aggregate number of fully diluted shares of our common stock from the first day of the preceding calendar year to the first day of the current calendar year or such lesser number as determined by our board of directors. On January 1, 2025, the number of shares of common stock available under the 2021 Plan increased to 156,512as per the Evergreen Feature in the 2021 Plan. Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock